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Abstract
Diabetic patients with acute coronary syndromesare at high risk for cardiovascular complicationsbut risk stratification in these patients remains
challenging. Regularly, diabetic patients have a less typ-
ical clinical presentation, which could lead to delayed
diagnosis and subsequent delayed initiation of treat-
ment. Since diabetic patients derive particular benefit
from aggressive anti-platelet therapy, early diagnostic
and therapeutic risk stratification of these patients is of
critical importance to improve their adverse outcome. 
Although the electrocardiogram remains a pivotal
diagnostic tool in the evaluation of patients suspected of
having an acute coronary syndrome, only significant ST-
segment changes provide reasonable prognostic infor-
mation. Therefore, repeated assessment of circulating
protein biomarkers represents a valuable diagnostic tool
for improving efficacy and safety of decision-making in
these patients. The combined use of biomarkers reflect-
ing distinct pathophysiological aspects, such as myocar-
dial necrosis, vascular inflammation, oxidative stress
and neurohumoral activation, may significantly improve
triage of patients with chest pain. These tools may iden-
tify those patients that are at particularly high risk for
short-term and/or long-term cardiovascular events.
Eventually, tailored medical and interventional treatment
of diabetic patients should help to prevent these cardiac
events in a cost-effective manner.
Diabetes Vasc Dis Res 2005;2:122–7
Key words: acute coronary syndrome, unstable angina,
biomarker, troponin, risk stratification.
Introduction
Acute coronary syndromes in diabetic patients present a
major challenge for risk stratification. Diabetes mellitus is a
major risk factor for cardiovascular morbidity and mortality.
The burden of cardiovascular disease associated with this
condition seems certain to increase dramatically because it
is estimated that the prevalence of diabetes will double by
the year 2025.1 Even when other risk factors are controlled,
individuals with diabetes have a three- to five-fold greater
risk of developing coronary artery disease than non-diabet-
ics.2 Diabetic patients with no history of heart disease have
the same risk for cardiovascular death as non-diabetics with
a history of myocardial infarction (MI).3 As many as 75% of
individuals with diabetes will die of coronary artery disease,2
and up to 33% of patients with insulin-dependent disease
will die by the age of 50 years.4 Most importantly, however,
coronary artery disease associated with diabetes has a more
aggressive clinical course. Diabetic patients suffer increased
mortality from both ST-segment elevation MI5,6 and non-ST-
segment elevation acute coronary syndromes (figure 1).7,8
Diabetics with acute coronary syndromes present more
commonly with clinical characteristics that are associated
with an adverse prognosis. Diabetics are more frequently
female, older, suffer from diffuse coronary heart disease,
more frequently have heart failure and have a less
favourable risk profile.7,8 Moreover, diabetic patients present
more often with less typical symptoms of an acute coronary
syndrome, and this may lead to delayed hospitalisation, pro-
longed diagnostic workup and postponed initiation of
appropriate treatment.9 Even after comprehensive statistical
adjustment for other prognostic factors, diabetics show an
increased mortality after onset of acute coronary syn-
dromes.7 These data clearly indicate that thorough risk strat-
ification in patients with diabetes is of critical importance for
their clinical outcome. 
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Figure 1.  Event rates (death, myocardial infarction) in
patients with acute coronary syndromes (with/without 
ST-segment elevations) during six months of follow-up
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For several decades, circulating biomarkers have been
used to assess myocardial injury in patients with suspected
non-ST-segment elevation acute coronary syndromes (NSTE-
acute coronary syndromes). However, biochemical markers
are now used not only to detect myocardial injury but also
for risk stratification and guidance of treatment in patients
with acute coronary syndromes.10-12 A substantial number of
studies support the use of cardiac troponins for the detection
of minor myocardial injury. Data for concurrent measure-
ment of markers of general inflammation (e.g. high-sensitiv-
ity C-reactive protein), markers of vascular inflammation
(e.g. placental growth factor), markers of platelet activation
(e.g. soluble CD40 ligand) and of neurohumoral activation
(e.g. brain natriuretic peptide) are currently emerging and it
may be that a multimarker approach will provide additional
information. Although markers that are not specific for the
coronary arteries and/or myocardium have their limitations,
they may be important tools for diagnostic and therapeutic
stratification of patients with acute coronary syndromes.
Cardiac troponins as specific markers of cardiac
necrosis (and thrombosis) 
Numerous studies provide convincing evidence that the
blood troponin level is a powerful indicator of risk for
patients with NSTE acute coronary syndromes13-23 whereas
creatine kinase-myocardial band (CK-MB) and myoglobin
are much less powerful predictors of the patient’s risk. A
meta-analysis of 14 trials showed that troponins are highly
predictive for the risk of death or acute MI. During 30-day
follow-up, the relative risk was 2.7 (95% confidence intervals
[CI] 2.1–3.4) in patients with unstable angina and elevated
troponin T. For troponin I the relative risk was 4.2 (95% CI
2.7–6.4).24 This predictive capacity of the troponins is inde-
pendent of important clinical risk factors, including age, ST-
segment deviations and presence of heart failure. Another
meta-analysis calculated a more than nine-fold increase in
the risk for death or MI in patients with elevated troponins.25
Angioscopic studies have revealed that the thrombus
responsible for the clinical manifestation of unstable angina
is more commonly white (platelet-rich) and less commonly
red (fibrin-rich), whereas red thrombus tends to be more
prominent in acute MI.26 Pathological studies in patients with
unstable angina who have died suddenly demonstrate that
the fatal event is often preceded by repetitive embolisation
of thrombi from an unstable atheroma.27,28 This results in
focal myocardial necrosis that is too small to be detected by
an increase in creatine kinase or CK-MB but that can be
detected by troponin measurements. Indeed, it has been
shown that troponin T elevation in patients with acute coro-
nary syndromes is significantly linked to visible thrombus,
even after prolonged treatment with heparin and in mor-
phologically complex target lesions.29 Failed resolution of
thrombus and complex lesion characteristics provided
important prognostic information. In a multivariable analysis,
however, troponin T represented the only independent and
the most powerful marker for the prediction of cardiac risk
in patients with acute coronary syndromes. 
The angiographic findings of this study are in full agree-
ment with the concept that troponin T release is related to
coronary thrombosis and consecutive embolisation, leading
to minor myocardial damage. Thus, even a small increase in
troponin levels in patients with acute coronary syndromes is
related to ‘minor myocardial injury’ and should be inter-
preted as an indicator for microembolisation from thrombus.
The increased cardiac risk of troponin T-positive patients
may be related less to minor myocardial damage and more
to complex coronary morphology and thrombus formation
in the culprit lesion. 
The acute phase reactant C-reactive protein as a
marker of general inflammation
Elevated levels of circulating cardiac troponin are found in
about one third of patients with acute coronary syndromes.
Although the absolute short-term risk of troponin-negative
patients is significantly lower as compared to troponin-posi-
tive patients, the large number of patients without troponin
elevation means that risk assessment and therapeutic man-
agement is clinically challenging. The six-month risk of death
or non-fatal MI in troponin-negative patients was 8.4% in the
c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina
(CAPTURE) trial.30 Therefore, the availability of a sensitive
marker of plaque instability, whose levels become elevated
before or even in the absence of myocardial necrosis, should
improve diagnostic and therapeutic decision-making. Over
the past decade, C-reactive protein (CRP), as a prototypic
but non-specific acute-phase reactant, has emerged as a
powerful predictor of cardiovascular events. There is com-
pelling epidemiological evidence that CRP is a sensitive
marker of inflammation and/or metabolic processes associ-
ated with atherogenesis and cardiovascular events such as
death, MI and stroke. 
Although CRP has been shown to be useful for risk
assessment in different populations,31,33 including patients
with acute coronary syndromes,34-36 debate about whether
CRP is a clinically useful biomarker continues. Danesh et al.
found in the Reykjavik prospective cohort study,33 which
included 2,459 patients with stable coronary heart disease
and 3,969 selected controls, that the predictive value of a
single baseline measurement of CRP for the 20-year inci-
dence of cardiovascular events was much less impressive
than previously reported values.37,38 Surprisingly, they found
that CRP adds little to the predictive value provided by the
assessment of traditional risk factors, including low-density
lipoprotein (LDL) cholesterol, whereas Ridker and co-work-
ers had previously reported that CRP had greater predictive
value than LDL.39 Since the Reykjavik study included by far
the largest number of events (albeit during a follow-up of 20
years) that have been studied in such analyses, these new
findings emphasise the need for more research to clarify the
use of CRP as a marker of cardiovascular risk in clinical prac-
tice. 
Two recent studies, one by Nissen et al.40 and one by
Ridker et al.,41 confirm that reducing the inflammatory com-
ponent of cardiovascular disease through the use of statin
therapy improves the clinical outcome independently of the
reduction in serum cholesterol levels. In the Reversal of
Atherosclerosis with Aggressive Lipid Lowering (REVERSAL)
trial, which included 502 patients with angiographically doc-
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umented stable coronary disease, the reduced rate of pro-
gression of atherosclerosis associated with intensive statin
treatment (80 mg atorvastatin), as compared with moderate
statin treatment (40 mg pravastatin), was significantly related
to greater reductions in the levels of both atherogenic
lipoproteins and CRP.40 In the Pravastatin or Atorvastatin
Evaluation and Infection Therapy-TIMI 22 (PROVE IT-TIMI
22) study, which included 3,745 patients with acute coro-
nary syndromes, atorvastatin 80 mg was more likely than
pravastatin 40 mg to result in low levels of LDL cholesterol
and CRP.41    However, meeting these targets was more impor-
tant in determining the patients’ outcome than was the spe-
cific choice of therapy. Patients who had low CRP levels after
statin therapy had better clinical outcomes than those with
higher CRP levels, regardless of the level of LDL cholesterol. 
The exact source of elevated CRP levels among patients
with acute coronary syndromes remains unclear. Given that
myocardial damage is also a major inflammatory stimulus, it
is important to note that, in a recent combined analysis of
the Fragmin and fast Revascularisation during InStability in
Coronary artery disease II (FRISC-II) trial and Global
Utilisation of Strategies to Open Occluded arteries
(GUSTO)-IV, CRP elevation over a period of up to 120 hours
after onset of symptoms was found only in patients with ele-
vated troponin levels.42 In CAPTURE patients, CRP levels
were consistently significantly higher in troponin-positive
patients,36 suggesting that an acute inflammatory process
induced by myocardial damage is superimposed on a chron-
ic inflammatory condition. Thus, current research activities
have shifted to the identification of more upstream markers
of the inflammatory cascade which may be more represen-
tative of vascular inflammation (figure 2).
Placental growth factor as a primary vascular
inflammatory instigator
Placental growth factor (PlGF), a member of the vascular
endothelial growth factor (VEGF) family, was recently shown
to be profoundly up-regulated in early and advanced athero-
sclerotic lesions.43 PlGF, originally identified in the placenta,44
stimulates vascular smooth muscle growth, recruits
macrophages into atherosclerotic lesions, up-regulates
tumour necrosis factor (TNF)α and monocyte chemoattrac-
tant protein (MCP)-1 production by macrophages, enhances
production of tissue factor and stimulates pathological angio-
genesis.43,45 All these processes are known contributors to
plaque progression and destabilisation. Most importantly,
inhibition of the PlGF effects by blocking its receptor Flt-1
was shown experimentally to suppress both atherosclerotic
plaque growth and vulnerability via inhibition of inflamma-
tory cell infiltration.46 These data suggest that PlGF may act
as a primary inflammatory instigator of atherosclerotic
plaque instability. 
PlGF blood levels are markedly up-regulated in patients
with acute coronary syndromes, independent of the pres-
ence of myocardial injury.47 Moreover, data from the CAP-
TURE trial established PlGF blood levels as a novel, power-
ful and independent prognostic determinant of clinical out-
come in patients with acute coronary syndromes.47
Measuring PlGF levels significantly extends the predictive
and prognostic information gained from traditional inflam-
matory markers in acute coronary syndromes. The predic-
tive value of PlGF levels was found to be independent of
myocardial necrosis as evidenced by elevated troponin lev-
els,29 and of platelet activation as evidenced by elevation of
soluble CD40 ligand.48 Intriguingly, elevated PlGF levels
identified not only those patients with acute chest pain who
developed acute coronary syndromes, but also those
patients who suffered from an increased risk of recurrent
instability after discharge after an initial acute coronary syn-
drome. PlGF levels may represent a reliable and powerful
clinical tool for identifying both patients with high-risk
lesions and those with ongoing vascular inflammation of the
coronary circulation.
The role of PlGF as a primary inflammatory instigator of
atherosclerotic lesion instability makes sense given its well
documented pro-inflammatory effects in animal models of
atherosclerosis and arthritis.43 Although PlGF belongs to the
VEGF family, its role in causation of disease appears to be
related more to vascular inflammation than to angiogene-
sis.46 Whereas VEGF is activated by hypoxia and elevation of
VEGF levels is regarded as an early adaptation of the
myocardium to deprivation of blood flow,49 PlGF is not
affected, and may even be down-regulated, by hypoxia.50,51
In line with these data, analysis of CAPTURE did not reveal
any correlation between PlGF levels and VEGF levels as a
marker of myocardial ischaemia or between PlGF levels and
troponin levels as a marker of myocardial necrosis. PlGF lev-
els do not appear to be confounded by myocardial necrosis,
whereas VEGF levels are linked to troponin elevation,
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Figure 2.  Earlier markers of vascular inflammatory and
thrombo-inflammatory activation, respectively, may precede
the development of myocardial injury (troponin release) or
neurohumoral activation (BNP or NT-proBNP release) 
in patients with acute coronary syndromes
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impaired TIMI flow and clinical evidence of myocardial
ischaemia.48 Most notably, since the pro-inflammatory effects
of PlGF can be specifically inhibited by blocking its receptor
Flt-1, these findings may also provide a rationale for a novel
anti-inflammatory therapeutic target in patients with coro-
nary artery disease.43
Soluble CD40 ligand as a marker for platelet activation
Troponins are surrogate markers for unstable thrombus for-
mation30 but more immediate biochemical markers of
platelet activation may prove to be helpful for identifying
patients who are in a prothrombotic state, even before
myocardial necrosis occurs. In this respect, increasing evi-
dence suggests that CD40 ligand is associated with platelet
activation.52 Soluble CD40 ligand is actively released follow-
ing platelet stimulation (figure 3).53,54 Circulating soluble
CD40 ligand can activate CD40 on endothelial cells and
thereby induce a pro-inflammatory cascade in the vessel
wall. Soluble CD40 ligand can also activate CD40 which is
expressed on inflammatory cells such as monocytes and T
cells. The subsequent activation of these inflammatory cells
and their invasion into the ruptured or eroded plaque results
in further inflammatory perturbation of the vessel wall. In
patients with coronary heart disease, soluble CD40 ligand is
released primarily from activated platelets; elevated levels
have been reported for patients with acute coronary syn-
dromes.55,56 Moreover, it has been shown that soluble CD40
ligand is a powerful biochemical marker of thrombotic
inflammatory activation in patients with acute coronary syn-
dromes, supporting the close relationship between inflam-
mation, thrombotic activation and acute coronary syn-
dromes.48,57 The latter two studies have clearly demonstrated
that combining this new marker with classical markers of
necrosis (troponins) can help us to identify those patients at
highest risk for subsequent cardiovascular events.
Natriuretic peptides as markers of neurohumoral
activation of the heart  
Since the description of elevated levels of the neurohor-
mone B-type natriuretic peptide (BNP) and the N-terminal
fragment of the BNP prohormone, NT-proBNP, in patients
with congestive heart failure, several investigations have
focused on the prognostic value of neurohumoral activation
in the setting of acute MI. More recently, the prognostic
implications of BNP and NT-proBNP, have also been extend-
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Figure 3.  The pathophysiological role of soluble CD40 ligand
in plaque destabilisation and thrombosis of patients with
acute coronary syndromes
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Figure 4.  Therapeutic benefit of treatment with glycoprotein
IIb/IIIa receptor antagonists in patients (a) with and (b)
without diabetes. Therapeutic benefit of treatment with
glycoprotein IIb/IIIa receptor antagonists in diabetic patients
treated by percutaneous coronary intervention (c) 
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ed to patients with unstable angina and non-ST-elevation
MI. In a first small case-control study of patients with non-
ST-elevation acute coronary syndromes, NT-proBNP levels
were higher among patients who died than those who sur-
vived.58 This pilot study was followed by a post hoc analysis
of the orbofiban in patients with unstable coronary syn-
dromes (OPUS)-TIMI 16 trial: this included 2,525 patients in
whom BNP was measured approximately 40 hours after the
onset of symptoms.59 Rates of death and heart failure during
10 months of follow-up increased with higher baseline lev-
els of BNP, and this finding was consistent across the spec-
trum of acute coronary syndromes. 
More recently, in a consecutive series of patients with
chest pain and no ST-segment elevation, Jernberg and col-
leagues also found that NT-proBNP levels measured at the
time of arrival in the emergency room were strongly associ-
ated with long-term mortality, again independent of the
index diagnosis (MI or unstable angina).60 A more recent
study in patients with stable coronary heart disease demon-
strated that elevated levels of BNP are independently associ-
ated with inducible ischaemia. This provides the rationale
for the hypothesis that NT-proBNP levels in patients with
acute coronary syndromes may also reflect ischaemia-
induced left ventricular dysfunction, even in the absence of
myocardial necrosis.61 
In a heterogeneous population of patients with non-ST
elevation acute coronary syndromes enrolled in the Platelet
Receptor Inhibition in Ischemic Syndrome Management
(PRISM) trial, it was demonstrated that serial measurements
of NT-proBNP significantly enhance the predictive value as
compared to a single baseline NT-proBNP measurement.62 A
second blood sample, drawn 72 hours after the onset of
symptoms, provided important information about the fur-
ther clinical course of the patients. A rapid fall in NT-proBNP
levels may indicate responsiveness to the therapeutic regi-
men chosen for the individual patient and, thus, may explain
the reduced event rates observed in patients with declining
NT-proBNP levels during the first days after onset of symp-
toms. Intriguingly, none of the other investigated biomarkers
(troponin T and CRP) demonstrated a similar pattern during
clinical stabilisation of these patients. These data suggest for
the first time that serial measurements of NT-proBNP in
patients with acute coronary syndromes can be used for
dynamic risk assessment and may be helpful for rapid iden-
tification of patients who are suitable for early discharge or
who may need more intensive therapy.
Summary
Diabetic patients represent a high-risk population of patients
with acute coronary syndromes. Unfortunately, clinical pre-
sentation in these patients is frequently not typical, which
can delay the diagnostic workup and initiation of appropri-
ate treatment. Since diabetic patients derive particular ben-
efit from aggressive antiplatelet therapy (figure 4),63 early risk
stratification of these patients is of great importance for their
short- and long-term prognosis. The electrocardiogram still
remains the most useful and cost-effective first-line tool in
the evaluation of patients with chest pain. After exclusion of
the presence of ST-segment elevation, repeat quantitative or
qualitative troponin measurements provide valuable diag-
nostic tools for improving efficacious and safe decision-mak-
ing in patients suspected of having an acute coronary syn-
drome. 
Increasing evidence suggests that the combined use of
biomarkers reflecting distinct pathophysiological features
such as myocardial necrosis, vascular inflammation, oxida-
tive stress and neurohumoral activation may add significant-
ly to our ability to identify correctly patients who are at high
risk for short-term and long-term cardiovascular events and
subsequently to tailor medical treatment to improve their
adverse outcome. 
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